In a sector note on U.S. Medical Supplies and Devices, UBS analyst Danielle Antalffy initiated coverage of Johnson & Johnson with a Neutral rating and $164 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson issues statement on Third Circuit review petition
- Johnson & Johnson put volume heavy and directionally bearish
- Johnson & Johnson’s (NYSE:JNJ) Decade-Low P/E Ratio Deserves Your Attention
- Janssen announces publication of data on dengue antiviral candidate
- Arcellx initiated with a Buy at Stifel